Supplementary Figures S1-S7 from Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers

Supplementary Figure S1 shows IC50 values of KRASG12C inhibitors for KRASG12C, NRASG12C, HRASG12C. Supplementary Figure S2 shows inhibition of NRASG12C by sotorasib in 293T and MOLT-4 cells. Supplementary Figure S3 shows effect of amino acid substitutions in NRASG12C or KRASG12C on signaling in response to sotorasib and adagrasib. Supplementary Figure S4 who's location of isoform-variable residues relative to Switch-II binders. Supplementary Figure S5 shows crystal structures of KRASG12C inhibitors and interactions with His95. Supplementary Figure S6 shows chemical structures of switch-II pocket-binding KRASG12C inhibitors. Supplementary Figure S7 shows structural model of sotorasib interaction with Leu95.